Corticosteroid treatment of prolidase deficiency skin lesions by inhibiting iminodipeptide-primed neutrophil superoxide generation.
We studied the pathogenetic role of iminodipeptides, and the effects of corticosteroids on the skin lesions of two adult female siblings with prolidase deficiency. The elder sister had had severe skin ulcers and mental retardation since childhood, while the younger sister had shown milder clinical manifestations since late adolescence. The ulcers showed vascular wall thickening and neutrophil infiltration. Oral prednisolone at moderate doses was not effective, but corticosteroid pulse therapy followed by a moderate dose of prednisolone improved the preulcerative indurated lesions and ulcers. A 2-year follow-up of the younger patient indicated that N-formyl methionyl leucyl phenylalanine-induced neutrophil superoxide generation was elevated, in parallel with an increase in the serum iminodipeptide level, when the skin ulcers and preulcerative indurated lesions were most active. Corticosteroid pulse therapy downregulated the superoxide generation by neutrophils. The serum iminodipeptide level, however, did not decrease during 25 days after pulse therapy. These findings suggest that iminodipeptides may play an important part in aggravating the skin lesions by priming neutrophil superoxide generation, and that high-dose corticosteroids improve the skin lesions, probably by inhibiting the infiltration, and superoxide generation by, neutrophils. Neutrophil superoxide generation was more prominent in the elder sister, suggesting that clinical severity may depend on the response of neutrophils to the iminodipeptides. Chronic stimulation by superoxide may cause thickening of cerebral blood vessels and eventual mental retardation.
Yasuda
K
K
Department of Dermatology, Kochi Medical School, Nankoku, Kochi, Japan.
Ogata
K
K
Kariya
K
K
Kodama
H
H
Zhang
J
J
Sugahara
K
K
Sagara
Y
Y
Kodama
H
H
D000328:Adult; D004150:Dipeptidases / Q000172:deficiency*; D004151:Dipeptides / Q000097:blood; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use*; D009504:Neutrophils / Q000378:metabolism; D012883:Skin Ulcer / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D013481:Superoxides / Q000378:metabolism
D004151:Dipeptides; D005938:Glucocorticoids; D013481:Superoxides; D004150:Dipeptidases; C022449:proline dipeptidase; D008775:Methylprednisolone